The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.
Government spokesman Thanakorn Wangboonkongchana said the drug, branded as Evusheld, was developed by AstraZeneca and registered in June last year.
It was authorised by the US Food and Drug Administration for emergency use in the US on Dec 8 last year, he said, adding it has also been approved by the European Union.
Evusheld is a combination of two long-acting antibodies (tixagevimab and cilgavimab) and works on the principle of “passive immunisation”.
It is administered as two injections, with protection lasting for at least six months.
Evusheld is given pre-emptively to people who have not yet been exposed to Covid-19, not people who are already infected with the virus.
It…
